Sysmex (OTCMKTS:SSMXY) Downgraded by Citigroup to Hold

Sysmex (OTCMKTS:SSMXY) was downgraded by analysts at Citigroup from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Sysmex Stock Performance

Shares of SSMXY opened at $8.61 on Monday. The stock has a market capitalization of $5.42 billion, a PE ratio of 17.94 and a beta of 1.14. The business’s fifty day moving average price is $9.33 and its 200 day moving average price is $10.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44. Sysmex has a 12-month low of $8.15 and a 12-month high of $19.65.

Sysmex (OTCMKTS:SSMXY) last released its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $837.32 million during the quarter, compared to analyst estimates of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. Equities research analysts forecast that Sysmex will post 0.57 EPS for the current year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.